Gilead agrees $5bn Tubulis deal — Financier Worldwide

BY Richard Summerfield Gilead Sciences has agreed to acquire Tubulis, a private, clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs), in a deal worth around $5bn. Under the terms of the sale and purchase agreement, Gilead will acquire all of t

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Financier Worldwide

NewsDataUK

Related Articles

Health

CAC 40 Drifts Lower As Oil Prices Rise Amid Truce Uncertainty

Unknown-3h ago-1 sources

Health

Map Shows Where SNAP Benefit Participation Is Plummeting Fastest

Giulia Carbonaro-3h ago-1 sources

Health

Pelican survived Lake Superior's cold - but not the hidden gunshot injuries

Unknown-4h ago-1 sources